Clik here to view.
Oncolytics’ Reolysin in new trial
The Children’s Oncology Group, in collaboration with the National Institutes of Health, intends to conduct a Phase 1 clinical trial of Oncolytics Biotech’s (TSX:ONC; NASDAQ:ONCY) Reolysin drug in...
View ArticleClik here to view.
Synthetic Biologics’ sniper approach to infectious diseases
Taking a page out of the oncology sector and its approach to targeting specific cancers with new biologics, Synthetic Biologics (NYSE MKT:SYN) is developing treatments for infectious diseases in much...
View ArticleClik here to view.
Gamida Cell shifts focus to NiCord stem cell product
Closely held Gamida Cell has shifted its focus to its second-generation stem cell product, NiCord, for the treatment of hematological malignancies and non-malignant hematological diseases in the wake...
View ArticleClik here to view.
Enrollment in Athersys stroke trial nears completion
Athersys (NASDAQ:ATHX) expects to complete enrollment by the end of the summer in a Phase 2 clinical trial of its MultiStem cell therapy in about 140 moderate to moderately-severe ischemic stroke...
View ArticleClik here to view.
Ciclofilin developing first drug for HCV/HIV-1 co-infection
Closely held Ciclofilin Pharmaceuticals is developing what, it hopes, will be the first clinically effective treatment for hepatitis C virus (HCV)/HIV-1 co-infection, with specific antiviral activity...
View Article
